Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
Abstract Introduction Our aim was to investigate the efficacy and safety of upadacitinib (UPA) in patients with either oligo- or polyarticular active psoriatic arthritis (PsA) using routine clinical practice data from an observational, prospective, multicentre study. Methods This interim analysis co...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-09-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-023-00589-3 |
| _version_ | 1827708402780864512 |
|---|---|
| author | Stephanie G. Werner Xenofon Baraliakos Sabine Reckert Martin Bohl-Bühler Marie-Claude Laliberté Tanya Girard Katharina Jeromin Nikola Baschuk Björn Fritz Louis Bessette Axel J. Hueber |
| author_facet | Stephanie G. Werner Xenofon Baraliakos Sabine Reckert Martin Bohl-Bühler Marie-Claude Laliberté Tanya Girard Katharina Jeromin Nikola Baschuk Björn Fritz Louis Bessette Axel J. Hueber |
| author_sort | Stephanie G. Werner |
| collection | DOAJ |
| description | Abstract Introduction Our aim was to investigate the efficacy and safety of upadacitinib (UPA) in patients with either oligo- or polyarticular active psoriatic arthritis (PsA) using routine clinical practice data from an observational, prospective, multicentre study. Methods This interim analysis contains upadacitinib efficacy and safety data from the UPJOINT study, collected from baseline to the week 24 visit with a focus on composite measures, clinical assessments and patient-reported outcomes, amongst others, including minimal disease activity (MDA), very low disease activity (VLDA), Disease Activity Index for Psoriatic Arthritis (DAPSA), Leeds Enthesitis Index (LEI), resolution of dactylitis and nail psoriasis and body surface area affected by skin psoriasis (BSA). Results A total of 296 patients with baseline data and 192 with completed week 24 visits were included in the analysis. The proportion of patients achieving MDA increased from 2.7% at baseline to 39.1% at week 24 (95% CI 32.1, 46.3). Similarly, the number of patients in DAPSA remission (DAPSA ≤ 4) increased from 0 at baseline to 32 (16.7%) by week 24. At that time, 59.4% of the patients were either in DAPSA remission or had low disease activity (DAPSA ≤ 14). During the 24 weeks time frame, the proportion of patients with BSA ≤ 3 increased from 80.7% to 91.1%. Furthermore, at weeks 12 and 24, 45.14% and 47.19% of affected patients showed a resolution of enthesitis. Active dactylitis and nail psoriasis at baseline were reported to affect 10.5% and 22.0%, decreasing to 2.6% and 5.7% at week 24, respectively. The safety findings are consistent with the known safety profile of upadacitinib in rheumatoid arthritis and PsA; no new safety risks were identified. Conclusion The data from this study confirm the findings of previous randomized controlled trials suggesting UPA is an effective treatment for active PsA without any new safety signals in patients from daily clinical practice. Clinical Trial Registration ClinicalTrials.gov identifier, NCT04758117. |
| first_indexed | 2024-03-10T17:03:07Z |
| format | Article |
| id | doaj.art-a787fb929fe14fb9989f5c14f59ca8bb |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-03-10T17:03:07Z |
| publishDate | 2023-09-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-a787fb929fe14fb9989f5c14f59ca8bb2023-11-20T10:53:24ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842023-09-011061503151810.1007/s40744-023-00589-3Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical PracticeStephanie G. Werner0Xenofon Baraliakos1Sabine Reckert2Martin Bohl-Bühler3Marie-Claude Laliberté4Tanya Girard5Katharina Jeromin6Nikola Baschuk7Björn Fritz8Louis Bessette9Axel J. Hueber10RHIO (Rheumatology, Immunology and Osteology) Duesseldorf and RHIO Research InstituteRheumazentrum Ruhrgebiet, Ruhr University BochumRheumatology and Osteology PracticeRheumahaus Potsdam GbRAbbVie CanadaAbbVie CanadaAbbVie Deutschland GmbH and Co. KGAbbVie Deutschland GmbH and Co. KGAbbVie Deutschland GmbH and Co. KGGroupe de Recherche en Rhumatologie et Maladies Osseuses (GRMO)Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum ErlangenAbstract Introduction Our aim was to investigate the efficacy and safety of upadacitinib (UPA) in patients with either oligo- or polyarticular active psoriatic arthritis (PsA) using routine clinical practice data from an observational, prospective, multicentre study. Methods This interim analysis contains upadacitinib efficacy and safety data from the UPJOINT study, collected from baseline to the week 24 visit with a focus on composite measures, clinical assessments and patient-reported outcomes, amongst others, including minimal disease activity (MDA), very low disease activity (VLDA), Disease Activity Index for Psoriatic Arthritis (DAPSA), Leeds Enthesitis Index (LEI), resolution of dactylitis and nail psoriasis and body surface area affected by skin psoriasis (BSA). Results A total of 296 patients with baseline data and 192 with completed week 24 visits were included in the analysis. The proportion of patients achieving MDA increased from 2.7% at baseline to 39.1% at week 24 (95% CI 32.1, 46.3). Similarly, the number of patients in DAPSA remission (DAPSA ≤ 4) increased from 0 at baseline to 32 (16.7%) by week 24. At that time, 59.4% of the patients were either in DAPSA remission or had low disease activity (DAPSA ≤ 14). During the 24 weeks time frame, the proportion of patients with BSA ≤ 3 increased from 80.7% to 91.1%. Furthermore, at weeks 12 and 24, 45.14% and 47.19% of affected patients showed a resolution of enthesitis. Active dactylitis and nail psoriasis at baseline were reported to affect 10.5% and 22.0%, decreasing to 2.6% and 5.7% at week 24, respectively. The safety findings are consistent with the known safety profile of upadacitinib in rheumatoid arthritis and PsA; no new safety risks were identified. Conclusion The data from this study confirm the findings of previous randomized controlled trials suggesting UPA is an effective treatment for active PsA without any new safety signals in patients from daily clinical practice. Clinical Trial Registration ClinicalTrials.gov identifier, NCT04758117.https://doi.org/10.1007/s40744-023-00589-3UpadacitinibPsoriatic arthritisEfficacySafetyMinimal disease activityVery low disease activity |
| spellingShingle | Stephanie G. Werner Xenofon Baraliakos Sabine Reckert Martin Bohl-Bühler Marie-Claude Laliberté Tanya Girard Katharina Jeromin Nikola Baschuk Björn Fritz Louis Bessette Axel J. Hueber Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice Rheumatology and Therapy Upadacitinib Psoriatic arthritis Efficacy Safety Minimal disease activity Very low disease activity |
| title | Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice |
| title_full | Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice |
| title_fullStr | Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice |
| title_full_unstemmed | Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice |
| title_short | Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice |
| title_sort | treatment with upadacitinib in active psoriatic arthritis efficacy and safety data of the first 192 patients from the upjoint study a multicentre observational study in clinical practice |
| topic | Upadacitinib Psoriatic arthritis Efficacy Safety Minimal disease activity Very low disease activity |
| url | https://doi.org/10.1007/s40744-023-00589-3 |
| work_keys_str_mv | AT stephaniegwerner treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT xenofonbaraliakos treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT sabinereckert treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT martinbohlbuhler treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT marieclaudelaliberte treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT tanyagirard treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT katharinajeromin treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT nikolabaschuk treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT bjornfritz treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT louisbessette treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice AT axeljhueber treatmentwithupadacitinibinactivepsoriaticarthritisefficacyandsafetydataofthefirst192patientsfromtheupjointstudyamulticentreobservationalstudyinclinicalpractice |